Ascites Hepatic
31
8
10
10
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.7%
3 terminated out of 31 trials
76.9%
-9.6% vs benchmark
6%
2 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (31)
SGLT-2 Inhibitors in the Treatment of Ascites
Early TIPS in Patients With Liver Cirrhosis and Ascites
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Underdilated-stent Technique Improves Post-TIPS Encephalopathy
A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis
Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
QOL and Sarcopenia in Patients With Ascites
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
Achieving Portal Access With Scorpion Post-Approval Study 2
Replicor Compassionate Access Program
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure
Empagliflozin in Diuretic Refractory Ascites
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
S100A8/A9 and Innate Immunity in Liver Disease
Empagliflozin as a Novel Therapy in Refractory Ascites
Comparison Between Conventional Angiocatheter Versus New Anchoring Device (KARAHOC) Used for Paracentesis